Project Grant HT9425261E463

The Defense Health Agency awarded $2.086 million to Universitat Bern on September 1, 2026, under the Military Medical Research and Development program (CFDA 12.420) to support research on minor spliceosome snRNA dysregulation as a diagnostic and therapeutic strategy in prostate cancer. The project runs through August 31, 2030, and is performed in Switzerland. The award funds basic and applied biomedical research aimed at transforming healthcare for Service Members and the American public through...

The Defense Health Agency awarded $3.499 million to Istituto DI Ricerche Farmacologiche Mario Negri on September 1, 2026, under the Military Medical Research and Development program (CFDA 12.420) to advance SUMO2 therapy toward clinical application in frontotemporal dementia. The project grant runs through August 31, 2030, with place of performance in Italy. The recipient is a private, independent biomedical research organization that develops new therapeutic approaches by investigating...

The Defense Health Agency awarded The Rockefeller University $1.649998 million on August 1, 2026, under the Military Medical Research and Development program (CFDA 12.420) to conduct therapeutic targeting of a commonly inherited breast cancer metastasis driver gene. Work performance is located in New York, NY with a period of performance through July 31, 2029. The Military Medical Research and Development program funds basic, applied, and advanced biomedical research to transform health care for...

The Defense Health Agency awarded Beckman Research Institute of The City of Hope $140,000 on September 1, 2026, under the Military Medical Research and Development program (CFDA 12.420) to enhance tumor-infiltrating lymphocyte (TIL) trafficking via paired cell engineering and lipid nanoparticle modulation of the tumor microenvironment in mucosal melanoma. The award period runs through August 31, 2027, with work performed at Beckman's facility in Irwindale, California. The Military Medical...

The Defense Health Agency awarded the Beckman Research Institute of the City of Hope $416,217 on September 30, 2026, under the Military Medical Research and Development program (CFDA 12.420) to develop photoacoustic computed tomography technology for identifying and diagnosing axillary lymph nodes in breast cancer patients without surgery. Performance runs through September 29, 2029, at the Institute's Irwindale, California research facility. The Military Medical Research and Development program...

The Defense Health Agency awarded Dana-Farber Cancer Institute, Inc. $2 million under the Military Medical Research and Development program (CFDA 12.420) on September 30, 2026, to support the Prostate Cancer Clinical Trials Consortium. The award funds clinical trial coordination and research activities from September 30, 2026, through September 29, 2030, at Dana-Farber's Boston, Massachusetts location. The Military Medical Research and Development program supports basic, applied, and advanced...

The Defense Health Agency awarded $248,797 to Universita' Degli Studi DI Napoli Federico II (Unina) on September 30, 2025, under the Military Medical Research and Development program (CFDA 12.420) to support research on chromatin-mediated epigenetic mechanisms underlying T and B cell immune responses in the sex bias of multiple sclerosis. Performance will occur in Italy through September 29, 2027. The Military Medical Research and Development program supports basic, applied, and advanced...

The Defense Health Agency awarded Yale University $1.05 million on July 1, 2026, under the Military Medical Research and Development program (CFDA 12.420) to conduct research on harnessing myeloid cell ontogeny to prevent melanoma brain metastasis. The award funds basic and applied biomedical research intended to transform health care for Service Members and the American public through innovative research and investigation of medical solutions for the battlefield. Performance will occur in New...

The Defense Health Agency awarded New York University School of Medicine $750,962 on June 15, 2026, under the Military Medical Research and Development program (CFDA 12.420) to investigate neoadjuvant checkpoint and IL-6 blockade mechanisms of benefit and toxicity. The award supports basic and applied biomedical research with a period of performance through June 14, 2029. Work is performed in New York, New York. The Military Medical Research and Development program funds research to transform...

The Defense Health Agency awarded Dana-Farber Cancer Institute, Inc. $1.12 million under the Military Medical Research and Development program (CFDA 12.420) on September 1, 2026, to support resource development to improve outcomes for blastic plasmacytoid dendritic cell neoplasm. The award funds basic and translational research over a four-year performance period ending August 31, 2030, with work performed in Boston, Massachusetts. The program supports innovative biomedical research to transform...